Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
Před 392 dny
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
Před 426 dny
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
Před 573 dny
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
Před 1154 dny
Sensex, Nifty Struggle For Direction In Early Trade
Indian shares were little changed on Friday, giving up early gains amid mounting concerns about the impact of U.S. tariffs on Indian goods.
RTTNews
|
Před 38 minutami
Australian Market Swings To Modest Gains In Mid-market
The Australian stock market is swinging to modest gains in mid-market moves on Friday after opening in the red, extending the gains in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is staying below the 9,000 mark, with gains in energy and technology stocks partially offset by weakness in mining and financial stocks.
RTTNews
|
Před 1 h 34 min
Asian Markets Mixed Amid Caution Trades
Asian stock markets are mixed on Friday, following the broadly positive cues from Wall Street overnight, ahead of the release of key U.S. inflation data later in the day that could impact the outlook for interest rates. Traders also digested highly anticipated earnings news from Nvidia, with the AI darling and market leader reporting second-quarter results that largely exceeded expectations.
RTTNews
|
Před 2 h 4 min
Sensex, Nifty Seen Tad Higher At Open As IIP Growth Recovers
Indian shares may open on a positive note on Friday after official data showed India's industrial output production expanded at the fastest pace in four months in July.
RTTNews
|
Před 2 h 37 min
